A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pneumocystis Jirovecii Pneumonia
- Sponsor
- National Taiwan University Hospital
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- High performance liquid chromatography for drug plasma concentration
- Last Updated
- 11 years ago
Overview
Brief Summary
In this study, we aim to investigate the incidence of the adverse reactions, the effectiveness and the gene polymorphism associated with the plasma level of sulfamethoxazole-trimethoprim and their metabolites (including N4-acetyl-sulfamethoxazole, sulfamethoxazole hydroxylamine and sulfamethoxazole-nitroso). And we also aim to investigate the factors associated with the sulfamethoxazole-trimethoprim induced acute psychosis.
Investigators
National Taiwan University Hospital
National Taiwan University Hospital
National Taiwan University Hospital
Eligibility Criteria
Inclusion Criteria
- •males and females aged 20 years or older
- •using oral or intravenous form of sulfamethoxazole-trimethoprim
Exclusion Criteria
- •patients who are under 20 years of age
Outcomes
Primary Outcomes
High performance liquid chromatography for drug plasma concentration
Time Frame: Participants will be followed for the duration of the treatment course, an expected average of 21 days
The plasma concentration will not be measured until the patient's treatment course completed.